- Market Realist•10 minutes ago
AbbVie (ABBV) expects to file a biologics license application for Rova-T as a third-line therapy for small cell lung cancer (or SCLC) in 2017.
- 24/7 Wall St.•1 hour ago
The August 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
- Market Realist•2 hours ago
AbbVie’s BCL-2 inhibitor drug Venclexta is expected to prove effective for the treatment of multiple types of blood cancers.
AbbVie Inc. (ABBV)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||64.90 x 300|
|Ask||64.91 x 500|
|Day's Range||64.74 - 65.32|
|52wk Range||45.45 - 68.12|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||18.80|
|Avg Vol (3m)||7,965,623|
|Dividend & Yield||2.28 (3.45%)|